Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Gains from Investment Securities (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 3 years of Gains from Investment Securities data on record, last reported at $539660.0 in Q4 2024.

  • For Q4 2024, Gains from Investment Securities changed N/A year-over-year to $539660.0; the TTM value through Sep 2025 reached $539660.0, changed N/A, while the annual FY2024 figure was $539660.0, 69.29% down from the prior year.
  • Gains from Investment Securities reached $539660.0 in Q4 2024 per COEP's latest filing, up from -$150000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $16.8 million in Q4 2021 and bottomed at -$14.2 million in Q1 2021.
  • Average Gains from Investment Securities over 3 years is -$29930.9, with a median of -$150000.0 recorded in 2022.
  • The widest YoY moves for Gains from Investment Securities: up 96.49% in 2022, down 136.31% in 2022.
  • A 3-year view of Gains from Investment Securities shows it stood at $16.8 million in 2021, then plummeted by 100.89% to -$150000.0 in 2022, then surged by 459.77% to $539660.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $539660.0 in Q4 2024, -$150000.0 in Q3 2022, and -$599176.0 in Q2 2022.